Background: Noncardiac surgical patients requiring postoperative vasopressors are biologically heterogeneous, yet current guidelines provide no validated bedside tool to stratify mean arterial pressure (MAP) targets by haemodynamic subtype.Methods: In this three-database retrospective cohort study, we analysed adult noncardiac postoperative patients with vasopressor-dependent hypotension (PVDH) in SICdb (discovery; n=2,700), MIMIC-IV (external validation; n=2,821), and eICU-CRD (external validation; n=1,478). Group-based trajectory modelling (GBTM) was fitted de novo in each database using simultaneous 24-hour trajectories of MAP, noradrenaline-equivalent (NEE) dose, and urine output. An eight-feature parsimonious XGBoost model trained on SICdb was externally validated to detect the highest-risk phenotype within six hours of vasopressor initiation.Findings: GBTM reproducibly identified three phenotypes: P0 (Perfusion-Preserved Recovery, 33–53%), P1 (Vasopressor-Dependent Stable, 33–56%), and P2 (Perfusion-Impaired Shock, 12–22%). P2 was characterised by escalating vasopressors, sustained hypotension, progressive oliguria, and hospital mortality 34·4–43·8%. Adjusted odds ratios for hospital mortality (P2 versus P0+P1) were 3·80 (95% CI 2·82–5·11), 3·43 (2·68–4·40), and 2·78 (2·01–3·85) in SICdb, MIMIC-IV, and eICU-CRD respectively (all p<0·0001); E-values 5·01–7·06. The eight-feature model achieved AUC 0·949 (SICdb cross-validation), 0·934 (95% CI 0·921–0·945) in MIMIC-IV, and 0·861 (0·838–0·883) in eICU-CRD. The vasopressor efficiency index (MAP/NEE) at initiation was 2·6- to 4·3-fold lower in P2 than P0 and declined progressively over 24 hours in MIMIC-IV P2 whereas P0 and P1 recovered—consistent with haemodynamic incoherence.Interpretation: Vasopressor-treated noncardiac postoperative patients comprise three reproducible haemodynamic phenotypes. P2, detectable within six hours using eight routine variables, carries three- to four-fold excess mortality linked to progressive vasopressor efficiency decline. This score provides the first externally validated bedside tool (pending prospective validation) addressing the individualised MAP target gap identified by guidelines, and defines enrichment criteria for precision resuscitation trials.